0001209191-21-068949.txt : 20211210 0001209191-21-068949.hdr.sgml : 20211210 20211210112709 ACCESSION NUMBER: 0001209191-21-068949 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211201 FILED AS OF DATE: 20211210 DATE AS OF CHANGE: 20211210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KELLY JUSTYNA CENTRAL INDEX KEY: 0001898344 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39373 FILM NUMBER: 211484334 MAIL ADDRESS: STREET 1: 4850 WEST 78TH STREET CITY: INDIANAPOLIS STATE: IN ZIP: 46268 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: POINT Biopharma Global Inc. CENTRAL INDEX KEY: 0001811764 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 850800493 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4850 WEST 78TH STREET CITY: INDIANAPOLIS STATE: IN ZIP: 46268 BUSINESS PHONE: (647) 401-2182 MAIL ADDRESS: STREET 1: 4850 WEST 78TH STREET CITY: INDIANAPOLIS STATE: IN ZIP: 46268 FORMER COMPANY: FORMER CONFORMED NAME: Therapeutics Acquisition Corp. DATE OF NAME CHANGE: 20200511 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2021-12-01 0 0001811764 POINT Biopharma Global Inc. PNT 0001898344 KELLY JUSTYNA 4850 WEST 78TH STREET INDIANAPOLIS IN 46268 0 1 0 0 Chief Operating Officer Stock Option (Right to Buy) 6.97 2026-11-03 Common Stock 26904 D Stock Option (Right to Buy) 8.47 2027-07-06 Common Stock 4932 D On June 30, 2021, POINT Biopharma Global Inc. (f/k/a Therapeutics Acquisition Corp., the "Issuer") consummated a business combination (the "Business Combination") pursuant to which RACA, Bodhi Merger Sub, Inc., a wholly-owned subsidiary of the Issuer, merged with and into POINT Biopharma Inc. ("Old POINT"). At the effective time of the Business Combination, each option to acquire shares of Old POINT was exchanged for an option to acquire shares of Common Stock of the Issuer based on an implied Old POINT vested equity value of $585,000,000. As a result, the Reporting Person received the reported options to acquire the Issuer's Common Stock in consideration for the options to acquire equity securities of Old POINT held by the Reporting Person prior to the Business Combination. The option vested 25% on November 3, 2021 with the remaining 75% vesting in three equal annual installments thereafter. The option vests 25% on July 6, 2022 with the remaining 75% vesting in three equal annual installments thereafter. Power of Attorney is attached to this Form 3 as Exhibit 24 /s/ William L. Demers, by Power of Attorney for Justyna Kelly 2021-12-10 EX-24 2 attachment1.htm EX-24 DOCUMENT

Exhibit 24

POWER OF ATTORNEY

	Know all by these presents, that the undersigned hereby constitutes and
appoints WILLIAM L. DEMERS, JAY H. KNIGHT, SUSAN V. SIDWELL, LAUREN A. BROWN,
ALISON H. SHORES and REBECCA WARE, with full power of substitution, the
undersigned's true and lawful attorney in fact to:

(1)	prepare, execute in the undersigned's name and on the undersigned's behalf,
and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID,
including amendments thereto, and any other documents necessary or appropriate
to obtain codes and passwords enabling the undersigned to make electronic
filings with the SEC of reports required by Section 16(a) of the Securities
Exchange Act of 1934 or any rule or regulation of the SEC;

(2)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer and/or director of POINT Biopharma Global Inc., a Delaware
corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a)
of the Securities Exchange Act of 1934 and the rules thereunder;

(3)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
complete and execute any amendment or amendments thereto, and timely file such
form with the SEC and any stock exchange or similar authority; and

(4)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney in fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney in fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney in fact may approve in such
attorney in fact's discretion.

	The undersigned hereby grants to each such attorney in fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney in fact, or such attorney
in fact's substitute or substitutes, shall lawfully do or cause to be done by
virtue of this power of attorney and the rights and powers herein granted.  The
undersigned acknowledges that the foregoing attorneys in fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys in fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 6th day of December, 2021.


			/s/ Justyna Kelly
			Signature

			Justyna Kelly
			Print Name